Eva A. S. Koster
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Eva A. S. Koster has a total of 94 co-authors. Here are the top co-authors by number of shared publications:
Liesbeth C. de Wreede
7 shared publications- Constantijn J. M. Halkes
Department of Hematology Leiden University Medical Center Leiden The Netherlands
5 shared publications Daniëlle van Lammeren
Department of Hematology, HagaZiekenhuis, The Hague, The Netherlands
5 shared publications- Peter van Balen
Department of Hematology, Leiden University Medical Center, Leiden, The Netherlands
5 shared publications Hendrik Veelken
Department of Hematology, Leiden University Medical Center, Leiden, Netherlands
4 shared publications- Liesbeth C. de Wreede
Department of Biomedical Data Sciences Leiden University Medical Center Leiden the Netherlands
4 shared publications
Latest Publications
- Open Access
- 20 October 2026
- Published by Wiley in Statistica Neerlandica
- Vol. 80 (4) , e70040
Capturing excess cause‐specific mortality during the COVID‐19 pandemic in the Netherlands using an advanced multi‐state model with relative survival
We present a new framework to estimate excess cause‐specific mortality by integrating relative survival into a multi‐state model, motivated by the question of how vaccination and infection impacted different components of excess mortality for the older Dutch population during the first two years of the COVID‐19 pandemic in the Netherlands. The proportion of the study population who died from COVID‐19, 0.98%, was nearly three times the excess proportion of all‐cause mortality, 0.34%, reflecting a mortality substitution effect: other causes of death occurred less than expected. COVID‐19 infection increased short‐term mortality across all causes of death, with residual risk beyond 28 days postinfection. Vaccination was associated with reduced COVID‐19 mortality risk in both the acute and long‐term infection phases, with consistent results across landmark times. Results suggest a healthy vaccinee bias, specifically for cardiovascular diseases, mental & neurological disorders and neoplasms. However, this bias seems far smaller than the impact of vaccination on reduction of COVID‐19 mortality.
- 20 October 2026
- Published by Wiley in Statistica Neerlandica
- Vol. 80 (4) , e70040
Open AccessCapturing excess cause‐specific mortality during the COVID‐19 pandemic in the Netherlands using an advanced multi‐state model with relative survival
We present a new framework to estimate excess cause‐specific mortality by integrating relative survival into a multi‐state model, motivated by the question of how vaccination and infection impacted different components of excess mortality for the older Dutch population during the first two years of the COVID‐19 pandemic in the Netherlands. The proportion of the study population who died from COVID‐19, 0.98%, was nearly three times the excess proportion of all‐cause mortality, 0.34%, reflecting a mortality substitution effect: other causes of death occurred less than expected. COVID‐19 infection increased short‐term mortality across all causes of death, with residual risk beyond 28 days postinfection. Vaccination was associated with reduced COVID‐19 mortality risk in both the acute and long‐term infection phases, with consistent results across landmark times. Results suggest a healthy vaccinee bias, specifically for cardiovascular diseases, mental & neurological disorders and neoplasms. However, this bias seems far smaller than the impact of vaccination on reduction of COVID‐19 mortality.
- Open Access
- 8 June 2026
- Published by Springer Nature in European Journal of Epidemiology
- Vol. 41 (7) , 869-880
Dynamics of infection, vaccination and excess mortality during the COVID-19 pandemic among older individuals—a nationwide analysis
The Coronavirus Diseases (COVID-19) pandemic led to excess mortality in many countries, i.e., to more deaths than expected. Older individuals generally had higher absolute risks of excess death. The complex dynamics of infection, vaccination and excess mortality have not yet been captured in one comprehensive model. With nationwide and unselected data from Statistics Netherlands, we analyzed the impact of documented infection and vaccination on excess mortality during 2020 and 2021 in the Dutch population aged over 63 on 1 January 2020 ( n = 3,826,770) by incorporating relative survival into a multi-state model considering COVID-19 (re)infection, vaccination and death. Background mortality was based on the observed mortality in 2015–2019 per sex, age and month of the year. All analyses were performed for the total cohort as well as stratified per sex and age category. The absolute excess mortality in 2020–2021 was 0.34% (95% confidence interval 0.32–0.37), comprising 4.41% of the observed mortality. It was higher in men (except in the youngest age group) and older individuals. Excess mortality occurred mostly during the first four weeks after a positive COVID-19 test, but also thereafter. If infection occurred after vaccination, excess mortality was still observed, but considerably less than without prior vaccination. These patterns were observed in all groups. In conclusion, these analyses demonstrate the substantial impact of COVID-19 on excess mortality during and after acute SARS-CoV-2 infection in individuals aged over 63 years. Moreover, the results show a reduction of excess mortality after vaccination for all groups in this cohort.
- 8 June 2026
- Published by Springer Nature in European Journal of Epidemiology
- Vol. 41 (7) , 869-880
Open AccessDynamics of infection, vaccination and excess mortality during the COVID-19 pandemic among older individuals—a nationwide analysis
The Coronavirus Diseases (COVID-19) pandemic led to excess mortality in many countries, i.e., to more deaths than expected. Older individuals generally had higher absolute risks of excess death. The complex dynamics of infection, vaccination and excess mortality have not yet been captured in one comprehensive model. With nationwide and unselected data from Statistics Netherlands, we analyzed the impact of documented infection and vaccination on excess mortality during 2020 and 2021 in the Dutch population aged over 63 on 1 January 2020 ( n = 3,826,770) by incorporating relative survival into a multi-state model considering COVID-19 (re)infection, vaccination and death. Background mortality was based on the observed mortality in 2015–2019 per sex, age and month of the year. All analyses were performed for the total cohort as well as stratified per sex and age category. The absolute excess mortality in 2020–2021 was 0.34% (95% confidence interval 0.32–0.37), comprising 4.41% of the observed mortality. It was higher in men (except in the youngest age group) and older individuals. Excess mortality occurred mostly during the first four weeks after a positive COVID-19 test, but also thereafter. If infection occurred after vaccination, excess mortality was still observed, but considerably less than without prior vaccination. These patterns were observed in all groups. In conclusion, these analyses demonstrate the substantial impact of COVID-19 on excess mortality during and after acute SARS-CoV-2 infection in individuals aged over 63 years. Moreover, the results show a reduction of excess mortality after vaccination for all groups in this cohort.
- Open Access
- 22 January 2026
- Published by Springer Nature in Annals of Hematology
- Vol. 105 (2) , 51
Anti-thymocyte globulin-based treatment frequently leads to enduring treatment success in both old and young adult patients with aplastic anaemia: a real-world analysis from the Dutch aplastic anaemia registry
Discussion remains concerning the safety and tolerability of anti-thymocyte globulin (ATG)-based immunosuppressive therapy (IST) in older patients with aplastic anaemia (AA). Using data of 127 consecutive patients from the Dutch adult AA registry, we evaluated long-term treatment success of standard ATG-based IST as first-line treatment with a multi-state model. Only one death was potentially associated with ATG. Overall survival at 5 years was 79%. We defined Transplantation-, Treatment- and Disease-Free Survival (TT-DFS) as the ultimate success of this treatment. This means that a patient is alive, is currently transfusion-independent without having received an allogeneic stem cell transplantation, has not developed AML or MDS, and has stopped all medication for AA. The probability of TT-DFS was 42% at 5 years after start of IST. In patients younger than 40 years ( n = 36) and in patients aged 60 or above ( n = 53), this was 58% and 34%, respectively. Older age, more severe AA and absence of a PNH-clone of ≥ 1% all reduced the likelihood of reaching TT-DFS. These analyses on unselected nationwide data indicate that ATG-based IST is effective and safe also in older patients. They suggest that age, AA severity and presence of a PNH-clone should be taken into account when considering this treatment in older patients.
- 22 January 2026
- Published by Springer Nature in Annals of Hematology
- Vol. 105 (2) , 51
Open AccessAnti-thymocyte globulin-based treatment frequently leads to enduring treatment success in both old and young adult patients with aplastic anaemia: a real-world analysis from the Dutch aplastic anaemia registry
Discussion remains concerning the safety and tolerability of anti-thymocyte globulin (ATG)-based immunosuppressive therapy (IST) in older patients with aplastic anaemia (AA). Using data of 127 consecutive patients from the Dutch adult AA registry, we evaluated long-term treatment success of standard ATG-based IST as first-line treatment with a multi-state model. Only one death was potentially associated with ATG. Overall survival at 5 years was 79%. We defined Transplantation-, Treatment- and Disease-Free Survival (TT-DFS) as the ultimate success of this treatment. This means that a patient is alive, is currently transfusion-independent without having received an allogeneic stem cell transplantation, has not developed AML or MDS, and has stopped all medication for AA. The probability of TT-DFS was 42% at 5 years after start of IST. In patients younger than 40 years ( n = 36) and in patients aged 60 or above ( n = 53), this was 58% and 34%, respectively. Older age, more severe AA and absence of a PNH-clone of ≥ 1% all reduced the likelihood of reaching TT-DFS. These analyses on unselected nationwide data indicate that ATG-based IST is effective and safe also in older patients. They suggest that age, AA severity and presence of a PNH-clone should be taken into account when considering this treatment in older patients.
- Open Access
- 20 October 2025
- Published by Springer Nature in Annals of Hematology
- Vol. 104 (10) , 5379-5387
Transplantation strategy affects the risk of GvHD after prophylactic and preemptive donor lymphocyte infusion
Donor lymphocyte infusion (DLI) after allogeneic stem cell transplantation (alloSCT) can boost Graft-versus-Leukaemia (GvL) reactivity but may induce Graft-versus-Host-Disease (GvHD). It is essential to understand which factors besides timing, donor type, and dose influence DLI alloreactivity. We previously identified viral infections, ≥ 5% patient cells in bone marrow chimerism, and lymphopenia at the time of DLI as relevant factors for GvHD after DLI following alemtuzumab-based T-cell depletion. Here, we investigated these factors and the alloreactivity after DLI following alloSCT with posttransplant cyclophosphamide in 83 patients with acute leukaemia/myelodysplastic syndrome receiving a prophylactic or preemptive DLI. 5% had viral infections close to DLI, 6% had ≥ 5% mixed chimerism, and 17% had lymphopenia. 2-year cumulative incidence of GvHD requiring systemic treatment was low: 7% (95%-confidence interval 1–14%). 22 of the 28 patients with ≥ 1% mixed chimerism at the time of DLI (79%) converted to full-donor chimerism. None of these responders relapsed, indicating achievement of GvL despite the low incidence of GvHD. Our data show that DLI alloreactivity is determined by the conditions at the time of DLI which are influenced by the transplantation strategy. Adjusting the DLI dose based on these conditions may improve the balance between GvHD and GvL.
- 20 October 2025
- Published by Springer Nature in Annals of Hematology
- Vol. 104 (10) , 5379-5387
Open AccessTransplantation strategy affects the risk of GvHD after prophylactic and preemptive donor lymphocyte infusion
Donor lymphocyte infusion (DLI) after allogeneic stem cell transplantation (alloSCT) can boost Graft-versus-Leukaemia (GvL) reactivity but may induce Graft-versus-Host-Disease (GvHD). It is essential to understand which factors besides timing, donor type, and dose influence DLI alloreactivity. We previously identified viral infections, ≥ 5% patient cells in bone marrow chimerism, and lymphopenia at the time of DLI as relevant factors for GvHD after DLI following alemtuzumab-based T-cell depletion. Here, we investigated these factors and the alloreactivity after DLI following alloSCT with posttransplant cyclophosphamide in 83 patients with acute leukaemia/myelodysplastic syndrome receiving a prophylactic or preemptive DLI. 5% had viral infections close to DLI, 6% had ≥ 5% mixed chimerism, and 17% had lymphopenia. 2-year cumulative incidence of GvHD requiring systemic treatment was low: 7% (95%-confidence interval 1–14%). 22 of the 28 patients with ≥ 1% mixed chimerism at the time of DLI (79%) converted to full-donor chimerism. None of these responders relapsed, indicating achievement of GvL despite the low incidence of GvHD. Our data show that DLI alloreactivity is determined by the conditions at the time of DLI which are influenced by the transplantation strategy. Adjusting the DLI dose based on these conditions may improve the balance between GvHD and GvL.
- Open Access
- 13 June 2025
- Published by Frontiers Media SA in Frontiers in Immunology
- Vol. 16, 1637094
Correction: Joint models quantify associations between immune cell kinetics and allo-immunological events after allogeneic stem cell transplantation and subsequent donor lymphocyte infusion
A correction refers to a change to their article that the author wishes to publish after publication. The publication of this article is subject to Frontiers' editorial approval.Instructions:• Please read through all the templates before choosing • Pick the most relevant text template(s) from the following page and delete all others.• Edit the text as necessary, ensuring that the original incorrect text is included for the record, please see the below. • Please do not use any extra formatting when editing the templates, and only modify the red text unless absolutely necessary • Submit to Frontiers following the instructions on this page.When the original text contained incorrect information, to preserve the scientific record, please include that text when editing the below templates. For example:There was a mistake in the Funding statement, an incorrect number was used. The correct number is '2015C03Bd051'. The publisher apologizes for this mistake.The original version of this article has been updated. In the published article, an author name was incorrectly written as Borne PAvd. The correct spelling is von dem Borne PA.The authors apologize for this error and state that this does not change the scientific conclusions of the article in any way. The original article has been updated.In the published article, there was an error in the Copyright statement. The statement was incorrectly written as "Copyright © 2023 Koster, Bonneville, Borne, van Balen, Marijt, Tjon, Snijders, van Lammeren, Veelken, Putter, Falkenburg, Halkes and de Wreede. This is an openaccess article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms." The corrected statement is "Copyright © 2023 Koster, Bonneville, von dem Borne, van Balen, Marijt, Tjon, Snijders, van Lammeren, Veelken, Putter, Falkenburg, Halkes and de Wreede. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms."The authors apologize for this error and state that this does not change the scientific conclusions of the article in any way. The original article has been updated.for a reason not seen here, please contact the journal's editorial office.
- 13 June 2025
- Published by Frontiers Media SA in Frontiers in Immunology
- Vol. 16, 1637094
Open AccessCorrection: Joint models quantify associations between immune cell kinetics and allo-immunological events after allogeneic stem cell transplantation and subsequent donor lymphocyte infusion
A correction refers to a change to their article that the author wishes to publish after publication. The publication of this article is subject to Frontiers' editorial approval.Instructions:• Please read through all the templates before choosing • Pick the most relevant text template(s) from the following page and delete all others.• Edit the text as necessary, ensuring that the original incorrect text is included for the record, please see the below. • Please do not use any extra formatting when editing the templates, and only modify the red text unless absolutely necessary • Submit to Frontiers following the instructions on this page.When the original text contained incorrect information, to preserve the scientific record, please include that text when editing the below templates. For example:There was a mistake in the Funding statement, an incorrect number was used. The correct number is '2015C03Bd051'. The publisher apologizes for this mistake.The original version of this article has been updated. In the published article, an author name was incorrectly written as Borne PAvd. The correct spelling is von dem Borne PA.The authors apologize for this error and state that this does not change the scientific conclusions of the article in any way. The original article has been updated.In the published article, there was an error in the Copyright statement. The statement was incorrectly written as "Copyright © 2023 Koster, Bonneville, Borne, van Balen, Marijt, Tjon, Snijders, van Lammeren, Veelken, Putter, Falkenburg, Halkes and de Wreede. This is an openaccess article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms." The corrected statement is "Copyright © 2023 Koster, Bonneville, von dem Borne, van Balen, Marijt, Tjon, Snijders, van Lammeren, Veelken, Putter, Falkenburg, Halkes and de Wreede. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms."The authors apologize for this error and state that this does not change the scientific conclusions of the article in any way. The original article has been updated.for a reason not seen here, please contact the journal's editorial office.
- Open Access
- 9 December 2024
- Published by BMJ in Journal for ImmunoTherapy of Cancer
- Vol. 12 (12) , e009564
DNA barcoded peptide-MHC multimers to measure and monitor minor histocompatibility antigen-specific T cells after allogeneic stem cell transplantation
Allogeneic stem cell transplantation (alloSCT) provides a curative treatment option for hematological malignancies. After HLA-matched alloSCT, donor-derived T cells recognize minor histocompatibility antigens (MiHAs), which are polymorphic peptides presented by HLA on patient cells. MiHAs are absent on donor cells due to genetic differences between patient and donor. T cells targeting broadly expressed MiHAs induce graft-versus-leukemia (GvL) reactivity as well as graft-versus-host disease (GvHD), while T cells for MiHAs with restricted or preferential expression on hematopoietic or non-hematopoietic cells may skew responses toward GvL or GvHD, respectively. Besides tissue expression, overall strength of GvL and GvHD is also determined by T-cell frequencies against MiHAs. Here, we explored the use of DNA barcode-labeled peptide-MHC multimers to detect and monitor antigen-specific T cells for the recently expanded repertoire of HLA-I-restricted MiHAs. In 16 patients who experienced an immune response after donor lymphocyte infusion, variable T-cell frequencies up to 30.5% of CD8+ T cells were measured for 49 MiHAs. High T-cell frequencies above 1% were measured in 12 patients for 19 MiHAs, with the majority directed against mismatched MiHAs, typically 6–8 weeks after donor lymphocyte infusion and at the onset of GvHD. The 12 patients included 9 of 10 patients with severe GvHD, 2 of 3 patients with limited GvHD and 1 of 3 patients without GvHD. In conclusion, we demonstrated that barcoded peptide-MHC multimers reliably detect and allow monitoring for MiHA-specific T cells during treatment to investigate the kinetics of immune responses and their impact on development of GvL and GvHD after HLA-matched alloSCT.
- 9 December 2024
- Published by BMJ in Journal for ImmunoTherapy of Cancer
- Vol. 12 (12) , e009564
Open AccessDNA barcoded peptide-MHC multimers to measure and monitor minor histocompatibility antigen-specific T cells after allogeneic stem cell transplantation
Allogeneic stem cell transplantation (alloSCT) provides a curative treatment option for hematological malignancies. After HLA-matched alloSCT, donor-derived T cells recognize minor histocompatibility antigens (MiHAs), which are polymorphic peptides presented by HLA on patient cells. MiHAs are absent on donor cells due to genetic differences between patient and donor. T cells targeting broadly expressed MiHAs induce graft-versus-leukemia (GvL) reactivity as well as graft-versus-host disease (GvHD), while T cells for MiHAs with restricted or preferential expression on hematopoietic or non-hematopoietic cells may skew responses toward GvL or GvHD, respectively. Besides tissue expression, overall strength of GvL and GvHD is also determined by T-cell frequencies against MiHAs. Here, we explored the use of DNA barcode-labeled peptide-MHC multimers to detect and monitor antigen-specific T cells for the recently expanded repertoire of HLA-I-restricted MiHAs. In 16 patients who experienced an immune response after donor lymphocyte infusion, variable T-cell frequencies up to 30.5% of CD8+ T cells were measured for 49 MiHAs. High T-cell frequencies above 1% were measured in 12 patients for 19 MiHAs, with the majority directed against mismatched MiHAs, typically 6–8 weeks after donor lymphocyte infusion and at the onset of GvHD. The 12 patients included 9 of 10 patients with severe GvHD, 2 of 3 patients with limited GvHD and 1 of 3 patients without GvHD. In conclusion, we demonstrated that barcoded peptide-MHC multimers reliably detect and allow monitoring for MiHA-specific T cells during treatment to investigate the kinetics of immune responses and their impact on development of GvL and GvHD after HLA-matched alloSCT.
- Open Access
- 27 November 2024
- Published by Elsevier in IJID Regions
- Vol. 14, 100500
Excess mortality during the first 2 years of the COVID-19 pandemic (2020-2021) in the Netherlands: Overall and across demographic subgroups
- 27 November 2024
- Published by Elsevier in IJID Regions
- Vol. 14, 100500
Open AccessExcess mortality during the first 2 years of the COVID-19 pandemic (2020-2021) in the Netherlands: Overall and across demographic subgroups
- Open Access
- 2 May 2024
- Published by American Society of Hematology in Blood
- Vol. 143 (18) , 1856-1872
Expanding the repertoire reveals recurrent, cryptic, and hematopoietic HLA class I minor histocompatibility antigens
Allogeneic stem cell transplantation (alloSCT) is a curative treatment for hematological malignancies. After HLA-matched alloSCT, antitumor immunity is caused by donor T cells recognizing polymorphic peptides, designated minor histocompatibility antigens (MiHAs), that are presented by HLA on malignant patient cells. However, T cells often target MiHAs on healthy nonhematopoietic tissues of patients, thereby inducing side effects known as graft-versus-host disease. Here, we aimed to identify the dominant repertoire of HLA-I-restricted MiHAs to enable strategies to predict, monitor or modulate immune responses after alloSCT. To systematically identify novel MiHAs by genome-wide association screening, T-cell clones were isolated from 39 transplanted patients and tested for reactivity against 191 Epstein-Barr virus transformed B cell lines of the 1000 Genomes Project. By discovering 81 new MiHAs, we more than doubled the antigen repertoire to 159 MiHAs and demonstrated that, despite many genetic differences between patients and donors, often the same MiHAs are targeted in multiple patients. Furthermore, we showed that one quarter of the antigens are cryptic, that is translated from unconventional open reading frames, for example long noncoding RNAs, showing that these antigen types are relevant targets in natural immune responses. Finally, using single cell RNA-seq data, we analyzed tissue expression of MiHA-encoding genes to explore their potential role in clinical outcome, and characterized 11 new hematopoietic-restricted MiHAs as potential targets for immunotherapy. In conclusion, we expanded the repertoire of HLA-I-restricted MiHAs and identified recurrent, cryptic and hematopoietic-restricted antigens, which are fundamental to predict, follow or manipulate immune responses to improve clinical outcome after alloSCT.
- 2 May 2024
- Published by American Society of Hematology in Blood
- Vol. 143 (18) , 1856-1872
Open AccessExpanding the repertoire reveals recurrent, cryptic, and hematopoietic HLA class I minor histocompatibility antigens
Allogeneic stem cell transplantation (alloSCT) is a curative treatment for hematological malignancies. After HLA-matched alloSCT, antitumor immunity is caused by donor T cells recognizing polymorphic peptides, designated minor histocompatibility antigens (MiHAs), that are presented by HLA on malignant patient cells. However, T cells often target MiHAs on healthy nonhematopoietic tissues of patients, thereby inducing side effects known as graft-versus-host disease. Here, we aimed to identify the dominant repertoire of HLA-I-restricted MiHAs to enable strategies to predict, monitor or modulate immune responses after alloSCT. To systematically identify novel MiHAs by genome-wide association screening, T-cell clones were isolated from 39 transplanted patients and tested for reactivity against 191 Epstein-Barr virus transformed B cell lines of the 1000 Genomes Project. By discovering 81 new MiHAs, we more than doubled the antigen repertoire to 159 MiHAs and demonstrated that, despite many genetic differences between patients and donors, often the same MiHAs are targeted in multiple patients. Furthermore, we showed that one quarter of the antigens are cryptic, that is translated from unconventional open reading frames, for example long noncoding RNAs, showing that these antigen types are relevant targets in natural immune responses. Finally, using single cell RNA-seq data, we analyzed tissue expression of MiHA-encoding genes to explore their potential role in clinical outcome, and characterized 11 new hematopoietic-restricted MiHAs as potential targets for immunotherapy. In conclusion, we expanded the repertoire of HLA-I-restricted MiHAs and identified recurrent, cryptic and hematopoietic-restricted antigens, which are fundamental to predict, follow or manipulate immune responses to improve clinical outcome after alloSCT.
- Open Access
- 13 March 2024
- Published by Frontiers Media SA in Frontiers in Immunology
- Vol. 15, 1335341
Risk factors for graft-versus-host-disease after donor lymphocyte infusion following T-cell depleted allogeneic stem cell transplantation
Introduction: Unmodified donor lymphocyte infusions (DLI) after allogeneic stem cell transplantation (alloSCT) can boost the beneficial Graft-versus-Leukemia (GvL) effect but may also induce severe Graft-versus-Host-Disease (GvHD). To improve the balance between GvL and GvHD, it is crucial to identify factors that influence the alloreactivity of DLI. Methods: We investigated the effects of the presence of patient-derived antigen-presenting cells at time of DLI as estimated by the bone marrow (BM) chimerism status, lymphopenia as measured by the absolute lymphocyte count (ALC) at time of DLI, and the presence of a viral infection (de novo or reactivation) close to DLI on the risk of GvHD after DLI. The cohort consisted of patients with acute leukemia or myelodysplastic syndrome who prophylactically or pre-emptively received DLI as standard care after alemtuzumab-based alloSCT. In patients at high risk for relapse, DLI was administered at 3 months after alloSCT (n=88) with a dose of 0.3x106 or 0.15x106 T cells/kg in case of a related or unrelated donor, respectively. All other patients (n=76) received 3x106 or 1.5x106 T cells/kg, respectively, at 6 months after alloSCT. Results: For both DLIs, patients with reduced-intensity conditioning and an unrelated donor had the highest risk of GvHD. For DLI given at three months, viral infection within 1 week before and 2 weeks after DLI was an additional significant risk factor (hazard ratio (HR) 3.66 compared to no viral infection) for GvHD. At six months after alloSCT, viral infections were rare and not associated with GvHD. In contrast, mixed BM chimerism (HR 3.63 for ≥5% mixed chimerism compared to full donor) was an important risk factor for GvHD after DLI given at six months after alloSCT. ALC of 6/l showed a trend for association with GvHD after this DLI (HR 2.05 compared to ≥1000x106/l, 95% confidence interval 0.94-4.45). Furthermore, the data suggested that the presence of a viral infection close to the DLI at three months or ≥5% mixed chimerism at time of the DLI at six months correlated with the severity of GvHD, thereby increasing their negative impact on the current GvHD-relapse-free survival. Conclusion: These data demonstrate that the risk factors for GvHD after DLI depend on the setting of the DLI.
- 13 March 2024
- Published by Frontiers Media SA in Frontiers in Immunology
- Vol. 15, 1335341
Open AccessRisk factors for graft-versus-host-disease after donor lymphocyte infusion following T-cell depleted allogeneic stem cell transplantation
Introduction: Unmodified donor lymphocyte infusions (DLI) after allogeneic stem cell transplantation (alloSCT) can boost the beneficial Graft-versus-Leukemia (GvL) effect but may also induce severe Graft-versus-Host-Disease (GvHD). To improve the balance between GvL and GvHD, it is crucial to identify factors that influence the alloreactivity of DLI. Methods: We investigated the effects of the presence of patient-derived antigen-presenting cells at time of DLI as estimated by the bone marrow (BM) chimerism status, lymphopenia as measured by the absolute lymphocyte count (ALC) at time of DLI, and the presence of a viral infection (de novo or reactivation) close to DLI on the risk of GvHD after DLI. The cohort consisted of patients with acute leukemia or myelodysplastic syndrome who prophylactically or pre-emptively received DLI as standard care after alemtuzumab-based alloSCT. In patients at high risk for relapse, DLI was administered at 3 months after alloSCT (n=88) with a dose of 0.3x106 or 0.15x106 T cells/kg in case of a related or unrelated donor, respectively. All other patients (n=76) received 3x106 or 1.5x106 T cells/kg, respectively, at 6 months after alloSCT. Results: For both DLIs, patients with reduced-intensity conditioning and an unrelated donor had the highest risk of GvHD. For DLI given at three months, viral infection within 1 week before and 2 weeks after DLI was an additional significant risk factor (hazard ratio (HR) 3.66 compared to no viral infection) for GvHD. At six months after alloSCT, viral infections were rare and not associated with GvHD. In contrast, mixed BM chimerism (HR 3.63 for ≥5% mixed chimerism compared to full donor) was an important risk factor for GvHD after DLI given at six months after alloSCT. ALC of 6/l showed a trend for association with GvHD after this DLI (HR 2.05 compared to ≥1000x106/l, 95% confidence interval 0.94-4.45). Furthermore, the data suggested that the presence of a viral infection close to the DLI at three months or ≥5% mixed chimerism at time of the DLI at six months correlated with the severity of GvHD, thereby increasing their negative impact on the current GvHD-relapse-free survival. Conclusion: These data demonstrate that the risk factors for GvHD after DLI depend on the setting of the DLI.